The application of double vital staining technique in macular epiretinal membrane surgery

doi:10.3877/cma.j.issn.2095-2007.2020.06.004

Abstract

Abstract:

Objective

The aim of this study was to investigate the application value of triamcinolone acetonide (TA) combined with indocyanine green (ICG) for posterior pole macular double vital staining during macular epiretinal membrane (ERM) surgery.

Methods

Retrospective cases series. From December 2015 to December 2018, 21 cases of ERM surgery were collected in Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University. Among of them, there were 5 males (5 eyes) and 16 females (16 eyes) with an average age of (66.0±13.9) years-old whose age range of was 53 to 79 years-old. The best corrected visual acuity (BCVA), optical coherence tomography (OCT) and complications were evaluated.

Results

All patients underwent 23G vitrectomy, in which 8 cases (8 eyes) accounting for 38.09% (8/21) underwent intraoperative phacoemulsification combined with intraocular lens implantation, 3 cases (3 eyes) accounting for 14.29% (3/21) with intraocular lens (IOL) before operation, 3 cases (3 eyes) accounting for 14.29% (3/21) with postoperative cataract surgery, and 7 cases accounting for 33.33% (7/21) with non-cataract surgery. The follow-up time after surgery was 13 to 36 months with average time of 18.52 months. There were 13 cases (13 eyes) whose BCVA was increased accounting for 69.10% (13/21), 6 cases (6 eyes) remained unchanged accounting for 28.57% (6/21), 2 cases (2 eyes) decreased accounting for 9.52% (2/21). OCT showed that the ERM had been removed completely. It was not found that recurrence during the follow-up period and complications occurred during and after the operation.

Conclusions

Double vital staining technique was a safe and effective method in ERM surgery, which has clinical application value.

Key words: Macular epiretinal membrane, Staining technique, Triamcinolone acetonide, Indocyanine green, Vitreous retinal surgery

Yongpeng Zhang, Yimeng Sun, Liyun Jia, Haiying Zhou, Kai Ma. The application of double vital staining technique in macular epiretinal membrane surgery[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(06): 339-344.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2020.06.004

https://zhykyxzz.cma-cmc.com.cn/EN/Y2020/V10/I06/339

Figures/Tables 2

References 30

[1]	Xiao W, Chen X, Yan W, et al. Prevalence and risk factors of epiretinal membranes: a systematic review and meta-analysis of population-based studies[J]. BMJ Open, 2017, 7(9): e014644.
[2]	You Q, Xu L, Jonas JB. Prevalence and associations of epiretinal membranes in adult Chinese: the Beijing eye study[J]. Eye, 2007, 22(7)：874-879.
[3]	William S, Claudia PP, Daniel A, et al. Epiretinal membrane: optical coherence tomography-based diagnosis and classification[J]. Clinical Ophthalmology, 2016, 10: 527-534.
[4]	Steel DHW, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment[J]. Eye, 2013, 27: S1-S21.
[5]	García-Layana A, García-Arumí J, Ruiz-Moreno JM, et al. A review of current management of vitreomacular traction and macular hole[J]. Journal of Ophthalmology, 2015: 809640.
[6]	Ota A, Tanaka Y, Toyoda F, et al. Relationship between variations in posterior vitreous detachment and visual prognosis in idiopathic epiretinal membranes[J]. Clin Ophthalmol, 2015, 10: 7-11.
[7]	Vogt D, Vielmuth F, Wertheimer C, et al. Premacular membranes in tissue culture[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(9): 1589-1597.
[8]	Sebag J. Anatomy and pathology of the vitreo-retinal interface[J]. Eye (Lond), 1992, 6 (Pt6): 541-552.
[9]	Chawla R, Tripathy K, Temkar S, et al. Internal limiting membrane: The innermost retinal barrier[J]. Med Hypotheses, 2017, 98: 60-62.
[10]	Chang WC, Chin L, Cho-Hao L, et al. Vitrectomy with or without internal limiting membrane peeling for idiopathic epiretinal membrane: A meta-analysis[J]. PLoS One, 2017, 12(6): e0179105.
[11]	Malagola R, Iozzo N, Grenga P. Volumetric assessment of the space between the posterior hyaloid and internal limiting membrane using SD-OCT[J]. Br J Ophthalmol, 2014, 98(1): 16-18.
[12]	Goldberg RA, Waheed NK, Duker JS. Optical coherence tomography in the preoperative and postoperative management of macular hole and epiretinal membrane[J]. British Journal of Ophthalmology, 2014, 98(S2): 20-23.
[13]	Francesco S, Francesco M, Sarah D, et al. Current trends about inner limiting membrane peeling in surgery for epiretinal membranes[J]. Journal of Ophthalmology, 2015: 671905.
[14]	Irini C, Panagiotis T, Luke N, et al. Advances in vitreoretinal interface disorders[J]. Journal of Ophthalmology, 2017: 7612712.
[15]	Schechet SA, Devience E, Thompson JT. The effect of internal limiting membrane peeling on idiopathic epiretinal membrane surgery, with a review of the literature[J]. Retina, 2017, 37(5): 870-880.
[16]	Azuma K, Ueta T, Eguchi S, et al. Effects of internal limiting membrane peeling combined with removal of idiopathic epiretinal membrane: a systematic review of literature and meta-analysis[J]. Retina, 2017, 37(10): 1813-1819.
[17]	Abdelkader E, Lois N. Internal limiting membrane peeling in vitreo-retinal surgery[J]. Surv Ophthalmol, 2008, 53(4)：368-396.
[18]	Koestinger A, Bovey EH. Visual acuity after vitrectomy and epiretinal membrane peeling with or without premacular indocyanine green injection[J]. European Journal of Ophthalmology, 2005, 15(6): 795.
[19]	Rodrigues EB, Meyer CH, Mennel S, et al. Mechanisms of intravitreal toxicity of indocyanine green dye: implications for chromovitrectomy[J]. Retina, 2007, 27(7): 958-970.
[20]	Stalmans P. Double vital staining using trypan blue and infracyanine green in macular pucker surgery[J]. Br J Ophthalmol, 2003, 87(6): 713-716.
[21]	Chen F, Zhang Y, Du W, et al. Indocyanine green-assisted internal limiting membrane peeling to induce posterior vitreous detachment in the cases with strong vitreoretinal adhesion[J]. Retina, 2019: 30893274.
[22]	Farah ME, Maia M, Rodrigues EB. Dyes in ocular surgery: principles for use in chromovitrectomy[J]. Am J Ophthalmol, 2009, 148(3): 332-340.
[23]	Farah ME, Maia M, Furlani B, et al. Current concepts of trypan blue in chromovitrectomy[J]. Dev Ophthalmol, 2008, 42: 91-100.
[24]	Enaida H, Ishibashi T. Brilliant blue in vitreoretinal surgery[J]. Dev Ophthalmol, 2008, 42: 115-125.
[25]	Gelman R, Stevenson W, Prospero PC, et al. Retinal damage induced by internal limiting membrane removal[J]. J Ophthalmol, 2015: 939748.
[26]	Hernández F, Alpizar-Alvarez N, Wu L. Chromovitrectomy: an update[J]. J Ophthalmic Vis Res, 2014, 9(2)：251-259.
[27]	Rosenberg KI, Tewari A. Visualizing the internal limiting membrane: what is effective and what is safe? [J]. Int Ophthalmol Clin, 2014, 54(2): 39-49.
[28]	Chatziralli IP, Theodossiadis PG, Steel DHW. Internal limiting membrane peeling in macular hole surgery; why, when, and how? [J]. Retina, 2018, 38(5): 870-882.
[29]	Al-Halafi AM. Chromovitrectomy: update[J]. Saudi J Ophthalmol, 2013, 27(4): 271-276.
[30]	Musat O, Stefan C, Boariu AM, et al. Chromovitrectomy[J]. Rom J Ophthalmol, 2016, 60(2): 59-62.

序号	性别	年龄(岁)	眼别	术前BCVA	视力下降时长(个月)	视物变形时长(个月)	联合白内障手术	术后二期白内障手术	术后随访时间(个月)	术后BCVA	术后视物变形的改善情况
1	女	58	左	0.25	12		否(术前IOL眼)		15	0.80
2	女	64	右	0.40		36	是		18	0.30	变形好转
3	女	66	右	0.30		12	是		15	1.50	变形好转
4	女	57	右	0.20	2	2	否	否	19	0.40	不变形
5	女	71	左	0.10	6		否	否	18	0.30
6	女	56	左	0.25	12		否	是	24	0.70
7	男	72	左	0.06	1		是		24	0.30
8	女	65	左	0.20		2	否	是	13	0.60	无改善
9	男	58	右	0.30	24		否	否	13	0.10
10	女	59	左	0.01	12		否(术前IOL眼)		13	0.01
11	女	58	左	0.20	8		否	是	13	0.70
12	女	65	右	0.10	5		否	否	13	0.10
13	女	60	左	0.30	3	3	否	否	14	0.30	不变形
14	女	74	右	0.10	12		是		18	0.10
15	男	79	左	0.20	5	5	是		13	0.30	变形好转
16	女	78	左	0.05	24		是		36	0.10
17	女	55	左	0.15	5	5	否	否	14	0.15	不变形
18	女	79	右	0.10	24	24	是		24	0.10	无改善
19	男	62	右	0.05	2		否(术前IOL眼)		24	0.60
20	女	53	左	0.10	1	1	否	否	35	0.90	变形好转
21	男	70	左	0.10	3		是		13	1.00

序号	性别	年龄(岁)	眼别	术前BCVA	视力下降时长(个月)	视物变形时长(个月)	联合白内障手术	术后二期白内障手术	术后随访时间(个月)	术后BCVA	术后视物变形的改善情况
1	女	58	左	0.25	12		否(术前IOL眼)		15	0.80
2	女	64	右	0.40		36	是		18	0.30	变形好转
3	女	66	右	0.30		12	是		15	1.50	变形好转
4	女	57	右	0.20	2	2	否	否	19	0.40	不变形
5	女	71	左	0.10	6		否	否	18	0.30
6	女	56	左	0.25	12		否	是	24	0.70
7	男	72	左	0.06	1		是		24	0.30
8	女	65	左	0.20		2	否	是	13	0.60	无改善
9	男	58	右	0.30	24		否	否	13	0.10
10	女	59	左	0.01	12		否(术前IOL眼)		13	0.01
11	女	58	左	0.20	8		否	是	13	0.70
12	女	65	右	0.10	5		否	否	13	0.10
13	女	60	左	0.30	3	3	否	否	14	0.30	不变形
14	女	74	右	0.10	12		是		18	0.10
15	男	79	左	0.20	5	5	是		13	0.30	变形好转
16	女	78	左	0.05	24		是		36	0.10
17	女	55	左	0.15	5	5	否	否	14	0.15	不变形
18	女	79	右	0.10	24	24	是		24	0.10	无改善
19	男	62	右	0.05	2		否(术前IOL眼)		24	0.60
20	女	53	左	0.10	1	1	否	否	35	0.90	变形好转
21	男	70	左	0.10	3		是		13	1.00

Please choose a citation manager

Content to export